BioWorld

Sep. 5, 2003

View Archived Issues

Epimmune Trimming Staff, Costs To Help Develop Pipeline Drugs

Epimmune Inc. reduced its staff by 23 percent and implemented other cost-cutting measures that the company said would give it enough operating funds to pull results from ongoing clinical trials in HIV and cancer. (BioWorld Today) Read More

Theratechnologies Enters Deal With J&J In Area Of Diabetes

Read More

Vaccine Spurs Immune System To Attack B. anthracis Plus Its Toxins, Beating Current Vaccines

Read More

Pozen Licenses MT 300 Rights To Xcel In Deal Worth At Least $10M

Read More

Cerus, Baxter Stop Phase III Of S-303 In Precautionary Move

Read More

Other News To Note

Read More